
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is facing short-term weakness due to sensationalized headlines regarding an adverse event reported to the FDA's unadjudicated FAERS database, but this is not related to their key product Foundayo. With an impressive projected EPS of $44.75 in 2027, based on a 27.5x multiple, Eli Lilly shows strong potential for long-term growth and has a BUY rating. Potential risks include slowing growth for key products, negative clinical data, emerging competitors, and broader sector headwinds.
Bears say
Eli Lilly is facing several fundamental risks that are likely to negatively impact its stock performance, including potential pricing and rebate pressures, weak sales trajectory for tirzepatide, disappointing launches of forglipron and pipeline products, and recent acquisitions that may not generate expected returns. These risks are reflected in the company's lower-than-expected 1Q26 EPS estimate of $6.73 compared to the consensus of $6.92, which includes a $0.52 impact from a disclosed IPR&D charge. These factors suggest a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares